Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion

Brian T. Kim, Stephen Schwartz, William E Smiddy, Rishi R. Doshi, Jaclyn Kovach, Audina Berrocal, Andrew A. Moshfeghi, Jorge Fortun

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

BACKGROUND AND OBJECTIVE: When delivered via a single intravitreal injection, ocriplasmin can effect proteolytic resolution of symptomatic vitreomacular adhesion (VMA). The authors describe their initial clinical experience with ocriplasmin at a large academic center. PATIENTS AND METHODS: Retrospective review of all patients with symptomatic VMA treated with ocriplasmin from January 2013 through May 2013 at a single center. RESULTS: Nineteen patients with symptomatic VMA received intravitreal ocriplasmin. Eight patients (42%) exhibited resolution of VMA. Macular holes in three of six patients (50%) closed after injection. A higher proportion of VMA resolution was observed in patients with the following baseline characteristics: age less than 65 years, focal adhesions less than or equal to 1,500 μm, presence of macular hole, phakic status, and absence of epiretinal membrane. CONCLUSION: Initial clinical outcomes using ocriplasmin in this study are consistent with those reported in the phase 3 clinical trials. Improved clinical results can be achieved with careful case selection based on specific baseline characteristics.

Original languageEnglish
Pages (from-to)334-343
Number of pages10
JournalOphthalmic Surgery Lasers and Imaging Retina
Volume44
Issue number4
DOIs
StatePublished - Jul 1 2013

Fingerprint

Retinal Perforations
Epiretinal Membrane
Therapeutics
Phase III Clinical Trials
Intravitreal Injections
Focal Adhesions
Status Epilepticus
microplasmin
Injections

ASJC Scopus subject areas

  • Ophthalmology
  • Surgery
  • Medicine(all)

Cite this

@article{fcda50a9820f40b4aee203ec3a79535f,
title = "Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion",
abstract = "BACKGROUND AND OBJECTIVE: When delivered via a single intravitreal injection, ocriplasmin can effect proteolytic resolution of symptomatic vitreomacular adhesion (VMA). The authors describe their initial clinical experience with ocriplasmin at a large academic center. PATIENTS AND METHODS: Retrospective review of all patients with symptomatic VMA treated with ocriplasmin from January 2013 through May 2013 at a single center. RESULTS: Nineteen patients with symptomatic VMA received intravitreal ocriplasmin. Eight patients (42{\%}) exhibited resolution of VMA. Macular holes in three of six patients (50{\%}) closed after injection. A higher proportion of VMA resolution was observed in patients with the following baseline characteristics: age less than 65 years, focal adhesions less than or equal to 1,500 μm, presence of macular hole, phakic status, and absence of epiretinal membrane. CONCLUSION: Initial clinical outcomes using ocriplasmin in this study are consistent with those reported in the phase 3 clinical trials. Improved clinical results can be achieved with careful case selection based on specific baseline characteristics.",
author = "Kim, {Brian T.} and Stephen Schwartz and Smiddy, {William E} and Doshi, {Rishi R.} and Jaclyn Kovach and Audina Berrocal and Moshfeghi, {Andrew A.} and Jorge Fortun",
year = "2013",
month = "7",
day = "1",
doi = "10.3928/23258160-20130715-05",
language = "English",
volume = "44",
pages = "334--343",
journal = "Ophthalmic Surgery Lasers and Imaging Retina",
issn = "2325-8160",
publisher = "Slack Incorporated",
number = "4",

}

TY - JOUR

T1 - Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion

AU - Kim, Brian T.

AU - Schwartz, Stephen

AU - Smiddy, William E

AU - Doshi, Rishi R.

AU - Kovach, Jaclyn

AU - Berrocal, Audina

AU - Moshfeghi, Andrew A.

AU - Fortun, Jorge

PY - 2013/7/1

Y1 - 2013/7/1

N2 - BACKGROUND AND OBJECTIVE: When delivered via a single intravitreal injection, ocriplasmin can effect proteolytic resolution of symptomatic vitreomacular adhesion (VMA). The authors describe their initial clinical experience with ocriplasmin at a large academic center. PATIENTS AND METHODS: Retrospective review of all patients with symptomatic VMA treated with ocriplasmin from January 2013 through May 2013 at a single center. RESULTS: Nineteen patients with symptomatic VMA received intravitreal ocriplasmin. Eight patients (42%) exhibited resolution of VMA. Macular holes in three of six patients (50%) closed after injection. A higher proportion of VMA resolution was observed in patients with the following baseline characteristics: age less than 65 years, focal adhesions less than or equal to 1,500 μm, presence of macular hole, phakic status, and absence of epiretinal membrane. CONCLUSION: Initial clinical outcomes using ocriplasmin in this study are consistent with those reported in the phase 3 clinical trials. Improved clinical results can be achieved with careful case selection based on specific baseline characteristics.

AB - BACKGROUND AND OBJECTIVE: When delivered via a single intravitreal injection, ocriplasmin can effect proteolytic resolution of symptomatic vitreomacular adhesion (VMA). The authors describe their initial clinical experience with ocriplasmin at a large academic center. PATIENTS AND METHODS: Retrospective review of all patients with symptomatic VMA treated with ocriplasmin from January 2013 through May 2013 at a single center. RESULTS: Nineteen patients with symptomatic VMA received intravitreal ocriplasmin. Eight patients (42%) exhibited resolution of VMA. Macular holes in three of six patients (50%) closed after injection. A higher proportion of VMA resolution was observed in patients with the following baseline characteristics: age less than 65 years, focal adhesions less than or equal to 1,500 μm, presence of macular hole, phakic status, and absence of epiretinal membrane. CONCLUSION: Initial clinical outcomes using ocriplasmin in this study are consistent with those reported in the phase 3 clinical trials. Improved clinical results can be achieved with careful case selection based on specific baseline characteristics.

UR - http://www.scopus.com/inward/record.url?scp=84881564220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881564220&partnerID=8YFLogxK

U2 - 10.3928/23258160-20130715-05

DO - 10.3928/23258160-20130715-05

M3 - Article

C2 - 23883268

AN - SCOPUS:84881564220

VL - 44

SP - 334

EP - 343

JO - Ophthalmic Surgery Lasers and Imaging Retina

JF - Ophthalmic Surgery Lasers and Imaging Retina

SN - 2325-8160

IS - 4

ER -